Skip to main content
Top
Published in: Cancer Causes & Control 9/2012

01-09-2012 | Original paper

Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient–nutrient interaction

Authors: Ting-Yuan David Cheng, Marian L. Neuhouser

Published in: Cancer Causes & Control | Issue 9/2012

Login to get access

Abstract

Objective

Excess vitamin A may interrupt vitamin D-mediated transcription of target genes. This study investigated whether serum 25-hydroxyvitamin D [25(OH)D] concentrations were associated with lung cancer mortality, and whether this association varied by excess circulating vitamin A and vitamin A/β-carotene supplement use.

Method

We analyzed 16,693 men and women in the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Lung cancer mortality (n = 258, 104 were former smokers and 23 were never smokers) were identified through National Death Index as of 2006. Serum 25(OH)D was measured by a radioimmunoassay. Vitamin A biomarkers including serum retinol, β-carotene, and retinyl esters were measured by HPLC. Supplement use for the past month was obtained by self-report. Multivariate-adjusted hazard ratios (HR) were estimated by Cox proportional hazard models.

Results

There was no association of serum 25(OH)D with overall lung cancer mortality. Among nonsmokers, ≥44 vs. <44 nmol/L of serum 25(OH)D was associated with a decreased risk (HR = 0.53, 95 % CI = 0.31–0.92, former/never smokers and HR = 0.31, 95 % CI = 0.13–0.77, distant-former [quit ≥20 years]/never smokers). The associations were not observed among participants with excess circulating vitamin A (serum retinyl esters ≥7.0 μg/dL or the ratio of retinyl esters to retinol ≥0.08) or vitamin A/β-carotene supplement users. However, statistical evidence to support effect modification of vitamin A was less clear.

Conclusions

Serum 25(OH)D concentrations were inversely associated with lung cancer mortality in nonsmokers. The beneficial association was diminished among those with excess circulating vitamin A or vitamin A/β-carotene supplement users.
Appendix
Available only for authorised users
Literature
1.
go back to reference Samet JM, Avila-Tang E, Boffetta P et al (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15:5626–5645PubMedCrossRef Samet JM, Avila-Tang E, Boffetta P et al (2009) Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15:5626–5645PubMedCrossRef
2.
go back to reference Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684–700PubMedCrossRef Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684–700PubMedCrossRef
3.
go back to reference Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW (2008) Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 181:7090–7099 Baltimore, Md.: 1950PubMed Hansdottir S, Monick MM, Hinde SL, Lovan N, Look DC, Hunninghake GW (2008) Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J Immunol 181:7090–7099 Baltimore, Md.: 1950PubMed
4.
go back to reference Menezes RJ, Cheney RT, Husain A et al (2008) Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 17:1104–1110PubMedCrossRef Menezes RJ, Cheney RT, Husain A et al (2008) Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Biomarkers Prev 17:1104–1110PubMedCrossRef
5.
6.
go back to reference Parise RA, Egorin MJ, Kanterewicz B et al (2006) CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119:1819–1828PubMedCrossRef Parise RA, Egorin MJ, Kanterewicz B et al (2006) CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 119:1819–1828PubMedCrossRef
7.
go back to reference Kim B, Lee HJ, Choi HY et al (2007) Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 67:7431–7438PubMedCrossRef Kim B, Lee HJ, Choi HY et al (2007) Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 67:7431–7438PubMedCrossRef
8.
go back to reference Chen G, Kim SH, King AN et al (2011) CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 17:817–826PubMedCrossRef Chen G, Kim SH, King AN et al (2011) CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res 17:817–826PubMedCrossRef
9.
go back to reference Ramnath N, Kim S, Christensen PJ (2011) Vitamin D and lung cancer. Expert Rev Respir Med 5:305–309PubMedCrossRef Ramnath N, Kim S, Christensen PJ (2011) Vitamin D and lung cancer. Expert Rev Respir Med 5:305–309PubMedCrossRef
10.
go back to reference Haussler MR, Haussler CA, Jurutka PW, et al. (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. The Journal of Endocrinology. 154 (Suppl): S57-73–S57-73 Haussler MR, Haussler CA, Jurutka PW, et al. (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. The Journal of Endocrinology. 154 (Suppl): S57-73–S57-73
11.
go back to reference Zou A, Elgort MG, Allegretto EA (1997) Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3–24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J Biol Chem 272:19027–19034PubMedCrossRef Zou A, Elgort MG, Allegretto EA (1997) Retinoid X receptor (RXR) ligands activate the human 25-hydroxyvitamin D3–24-hydroxylase promoter via RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D3. J Biol Chem 272:19027–19034PubMedCrossRef
12.
go back to reference Arnhold T, Tzimas G, Wittfoht W, Plonait S, Nau H. (1996) Identification of 9-cis-retinoic acid, 9,13-di-cis-retinoic acid, and 14-hydroxy-4,14-retro-retinol in human plasma after liver consumption. Life Sci 59: PL169–77 Arnhold T, Tzimas G, Wittfoht W, Plonait S, Nau H. (1996) Identification of 9-cis-retinoic acid, 9,13-di-cis-retinoic acid, and 14-hydroxy-4,14-retro-retinol in human plasma after liver consumption. Life Sci 59: PL169–77
13.
go back to reference Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL (2007) Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Am J Epidemiol 165:1178–1186PubMedCrossRef Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL (2007) Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Am J Epidemiol 165:1178–1186PubMedCrossRef
14.
go back to reference Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS (2010) Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102:1422–1427PubMedCrossRef Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS (2010) Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer 102:1422–1427PubMedCrossRef
15.
go back to reference Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D (2011) Serum 25-hydroxyvitamin d and risk of lung cancer in male smokers: a nested case-control study. PLoS One 6:e20796PubMedCrossRef Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D (2011) Serum 25-hydroxyvitamin d and risk of lung cancer in male smokers: a nested case-control study. PLoS One 6:e20796PubMedCrossRef
16.
go back to reference Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI (2010) Serum vitamin D and cancer mortality in the NHANES III study (1988–2006). Cancer Res 70:8587–8597PubMedCrossRef Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI (2010) Serum vitamin D and cancer mortality in the NHANES III study (1988–2006). Cancer Res 70:8587–8597PubMedCrossRef
17.
go back to reference Freedman DM, Looker AC, Chang S-C, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602PubMedCrossRef Freedman DM, Looker AC, Chang S-C, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594–1602PubMedCrossRef
18.
go back to reference Kilkkinen A, Knekt P, Heliövaara M et al (2008) Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 17:3274–3278PubMedCrossRef Kilkkinen A, Knekt P, Heliövaara M et al (2008) Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol Biomarkers Prev 17:3274–3278PubMedCrossRef
19.
go back to reference Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRef
20.
go back to reference Willett W (1998) Nutritional epidemiology, 2nd edn. Oxford University Press, OxfordCrossRef Willett W (1998) Nutritional epidemiology, 2nd edn. Oxford University Press, OxfordCrossRef
21.
go back to reference Mannino DM, Gagnon RC, Petty TL, Lydick E (2000) Obstructive lung disease and low lung function in adults in the United States: data from the national health and nutrition examination survey, 1988–1994. Arch Intern Med 160:1683–1689PubMedCrossRef Mannino DM, Gagnon RC, Petty TL, Lydick E (2000) Obstructive lung disease and low lung function in adults in the United States: data from the national health and nutrition examination survey, 1988–1994. Arch Intern Med 160:1683–1689PubMedCrossRef
22.
go back to reference Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30:771–777PubMedCrossRef Looker AC, Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR (2002) Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30:771–777PubMedCrossRef
23.
go back to reference Gunter EW, Lewis BG, Koncikowski SM (1996) Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994 Gunter EW, Lewis BG, Koncikowski SM (1996) Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994
24.
go back to reference Cheung YB (2007) A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 166:1337–1344PubMedCrossRef Cheung YB (2007) A modified least-squares regression approach to the estimation of risk difference. Am J Epidemiol 166:1337–1344PubMedCrossRef
25.
go back to reference Knoke JD, Burns DM, Thun MJ (2008) The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control 19:207–219PubMedCrossRef Knoke JD, Burns DM, Thun MJ (2008) The change in excess risk of lung cancer attributable to smoking following smoking cessation: an examination of different analytic approaches using CPS-I data. Cancer Causes Control 19:207–219PubMedCrossRef
26.
go back to reference Ebbert JO, Yang P, Vachon CM et al (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21:921–926PubMedCrossRef Ebbert JO, Yang P, Vachon CM et al (2003) Lung cancer risk reduction after smoking cessation: observations from a prospective cohort of women. J Clin Oncol 21:921–926PubMedCrossRef
27.
go back to reference Tong L, Spitz MR, Fueger JJ, Amos CA (1996) Lung carcinoma in former smokers. Cancer 78:1004–1010PubMedCrossRef Tong L, Spitz MR, Fueger JJ, Amos CA (1996) Lung carcinoma in former smokers. Cancer 78:1004–1010PubMedCrossRef
28.
go back to reference Ballew C, Galuska D, Gillespie C (2001) High serum retinyl esters are not associated with reduced bone mineral density in the third national health and nutrition examination survey, 1988–1994. J Bone Miner Res 16:2306–2312PubMedCrossRef Ballew C, Galuska D, Gillespie C (2001) High serum retinyl esters are not associated with reduced bone mineral density in the third national health and nutrition examination survey, 1988–1994. J Bone Miner Res 16:2306–2312PubMedCrossRef
29.
go back to reference IOM (Institute of Medicine) (2011) Overview of Vitamin D. Dietary Reference Intake for Calcium and Vitamin D. Washington, DC: The National Academics Press IOM (Institute of Medicine) (2011) Overview of Vitamin D. Dietary Reference Intake for Calcium and Vitamin D. Washington, DC: The National Academics Press
30.
go back to reference Park YK, Kim I, Yetley EA (1991) Characteristics of vitamin and mineral supplement products in the United States. Am J Clin Nutr 54:750–759PubMed Park YK, Kim I, Yetley EA (1991) Characteristics of vitamin and mineral supplement products in the United States. Am J Clin Nutr 54:750–759PubMed
31.
go back to reference Bailey RL, Gahche JJ, Lentino CV et al (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266PubMedCrossRef Bailey RL, Gahche JJ, Lentino CV et al (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266PubMedCrossRef
32.
go back to reference Higashimoto Y, Ohata M, Nishio K et al (1996) 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16:2653–2659PubMed Higashimoto Y, Ohata M, Nishio K et al (1996) 1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16:2653–2659PubMed
33.
go back to reference Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-Dihydroxycholecalciferol (1,25–D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644–2649PubMed Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS (1999) 1,25-Dihydroxycholecalciferol (1,25–D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res 59:2644–2649PubMed
34.
go back to reference Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS (1997) Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759–3764PubMed Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS (1997) Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57:3759–3764PubMed
35.
go back to reference Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T (2005) 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26:1044–1054PubMedCrossRef Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T (2005) 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26:1044–1054PubMedCrossRef
36.
go back to reference Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220PubMedCrossRef Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220PubMedCrossRef
37.
go back to reference Bao BY, Yao J, Lee YF (2006) 1 Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883–1893PubMedCrossRef Bao BY, Yao J, Lee YF (2006) 1 Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883–1893PubMedCrossRef
39.
go back to reference Zhou W, Suk R, Liu G et al (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14:2303–2309PubMedCrossRef Zhou W, Suk R, Liu G et al (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14:2303–2309PubMedCrossRef
40.
go back to reference Millen AE, Bodnar LM (2008) Vitamin D assessment in population-based studies: a review of the issues. Am J Clin Nutr 87:1102S–1105SPubMed Millen AE, Bodnar LM (2008) Vitamin D assessment in population-based studies: a review of the issues. Am J Clin Nutr 87:1102S–1105SPubMed
41.
go back to reference Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP (2010) Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19:927–931PubMedCrossRef Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP (2010) Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19:927–931PubMedCrossRef
Metadata
Title
Serum 25-hydroxyvitamin D, vitamin A, and lung cancer mortality in the US population: a potential nutrient–nutrient interaction
Authors
Ting-Yuan David Cheng
Marian L. Neuhouser
Publication date
01-09-2012
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 9/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0033-8

Other articles of this Issue 9/2012

Cancer Causes & Control 9/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine